MedTrace Logo

Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer

NCT02103062 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2020-04-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy of Abraxane (nab-paclitaxel) in subjects with previously treated metastatic colorectal cancer. Subjects will be placed into two separate cohorts based on their RAS mutation status.

Conditions

  • Colorectal Neoplasms

Interventions

DRUG

ABI-007

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Alfredo Romano, MD · Celgene

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-05
Primary Completion
2014-11-10
Completion
2015-01-09

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02103062 on ClinicalTrials.gov